RxDoctor Payments Data

Susan Suleske, PA

Physician Assistant · Culpeper, VANPI 1982928735

Payments from drug & device makers

$2,375in general payments, 2019–2025

Across 136 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$450
  • Novo Nordisk$366
  • IBSA Pharma Inc.$273
  • AstraZeneca$262
  • AbbVie$191
  • Lilly USA, LLC$185
  • plus $648 from 15 others

What the payments were for

  • Food & beverage$2,375100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,375 in reported general payments places this provider in the 85th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$65,958
Medicare patients
215
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate53$54,471
EliquisApixaban36$47,011
OzempicSemaglutide33$32,513
FarxigaDapagliflozin Propanediol41$32,421
Spiriva HandihalerTiotropium Bromide41$26,584
Tresiba Flextouch U-200Insulin Degludec15$24,046
RybelsusSemaglutide17$21,569
XareltoRivaroxaban17$14,498
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,067
BelsomraSuvorexant12$5,346
Spiriva RespimatTiotropium Bromide11$5,131
Fluticasone-SalmeterolFluticasone Propion/Salmeterol36$4,184
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,649
Advair HfaFluticasone Propion/Salmeterol11$3,450
Rosuvastatin Calcium179$2,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Belsomra$41$59,81765 claims
Novo NordiskOzempic, Rybelsus$366$54,08150 claims
PfizerEliquis$450$47,01136 claims
AstraZenecaFarxiga$262$32,42141 claims
Boehringer IngelheimSpiriva Respimat$19$5,13111 claims
AbbVieSynthroid$191$1,02725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Culpeper

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →